Anti-IL-33 Antibody Has a Therapeutic Effect in an Atopic Dermatitis Murine Model Induced by 2, 4-Dinitrochlorobenzene
- 745 Downloads
IL-33 is a new member of the IL-1 family that plays a role in allergic disease. In this study, we evaluated the potential on the inhibition of atopic dermatitis (AD) of anti-mouse IL-33 antibody (αIL-33Ab) using 2, 4-dinitrochlorobenzene (DNCB)-induced AD mice model. We treated mice with αIL-33Ab via subcutaneous injection of each DNCB treatment 1 h later from day 1 to day 33 for 14 times. A control group received tacrolimus. Skin lesion and scratching behavior were compared. Ear thickness, dermatitis score, eosinophils and mast cells infiltration, and serum IgE levels were also analyzed. Correlations between serum IL-33 as well as soluble(s) ST2 and AD disease activity index in human AD were also investigated. DNCB-induced AD-like mice treated with αIL-33Ab showed improved AD-like symptoms. Eosinophils and mast cells infiltration and serum IgE levels were also significantly reduced by αIL-33Ab. Our study suggests that blockade of IL-33 has a curative effect on AD.
KEY WORDSIL-33 αIL-33Ab atopic dermatitis DNCB inhibition
This work was supported by Scientific Research General Project of Educational Department in Liaoning Province of China in 2014 (Grant No. L2014295) and Science and Technology Project of Shenyang (Grant No. 17-230-9-25). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Compliance with Ethical Standards
The study adhered to the tenets of the Declaration of Helsinki. The study was approved by the local ethical committee (2016PS001K) and oral consent was obtained from all individuals.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.Karuppagounder, V., S. Arumugam, R.A. Thandavarayan, V. Pitchaimani, R. Sreedhar, R. Afrin, M. Harima, H. Suzuki, M. Nomoto, S. Miyashita, K. Suzuki, M. Nakamura, K. Ueno, and K. Watanabe. 2015. Tannic acid modulates NF휅B signaling pathway and skin inflammation in NC/Nga mice through PPAR훾 expression. Cytokine 76 (2): 206–213. https://doi.org/10.1016/j.cyto.2015.05.016.CrossRefPubMedGoogle Scholar
- 7.Chow, J.Y., C.K. Wong, P.F. Cheung, and C.W. Lam. 2010. Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel Th2 cytokine IL-33: implications for allergic inflammation. Cellular & Molecular Immunology 7 (1): 26–34. https://doi.org/10.1038/cmi.2009.106.CrossRefGoogle Scholar
- 8.Olivry, T., D. Mayhew, J.S. Paps, K.E. Linder, C. Peredo, D. Rajpal, H. Hofland, and J. Cote-Sierra. 2016. Early activation of Th2/Th22 inflammatory and pruritogenic pathways in acute canine atopic dermatitis skin lesions. The Journal of Investigative Dermatology 136 (10): 1961–1969. https://doi.org/10.1016/j.jid.2016.05.117.CrossRefPubMedGoogle Scholar
- 9.Schmitz, J., A. Owyang, E. Oldham, Y. Song, E. Murphy, T.K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, X. Li, D.M. Gorman, J.F. Bazan, and R.A. Kastelein. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 (5): 479–490.CrossRefPubMedGoogle Scholar
- 13.Pecaric-Petkovic, T., S.A. Didichenko, S. Kaempfer, N. Spiegl, and C.A. Dahinden. 2009. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 113 (7): 1526–1534. https://doi.org/10.1182/blood-2008-05-157818.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Li, C., I. Maillet, C. Mackowiak, C. Viala, F. Di Padova, M. Li, D. Togbe, V. Quesniaux, Y. Lai, and B. Ryffel. 2017. Experimental atopic dermatitis depends on IL-33R signaling via MyD88 in dendritic cells. Cell Death & Disease 8 (4): e2735. https://doi.org/10.1038/cddis.2017.90.CrossRefGoogle Scholar
- 17.Mizutani, N., T. Nabe, and S. Yoshino. 2013. Interleukin-33 and alveolar macrophages contribute to the mechanisms underlying the exacerbation of IgE-mediated airway inflammation and remodelling in mice. Immunology 139 (2): 205–218. https://doi.org/10.1111/imm.12071.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Hanifin, J.M., and G. Rajka. 1980. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 92 (Suppl): 44–47.Google Scholar
- 19.Severity scoring of atopic dermatitis: the SCORAD index. 1993. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 186(1):23–31.Google Scholar
- 20.Kilkenny, C., W. Browne, I.C. Cuthill, M. Emerson, D.G. Altman, and NC3Rs Reporting Guidelines Working Group. 2010. Animal research: reporting in vivo experiments: the ARRIVE guidelines. British Journal of Pharmacology 160 (7): 1577–1579. https://doi.org/10.1111/j.1476-5381.2010.00872.x.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.McGrath, J., G. Drummond, E. Mclachlan, C. Kilkenny, and C.L. Wainwright. 2010. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. British Journal of Pharmacology 160 (7): 1573–1576. https://doi.org/10.1111/j.1476-5381.2010.00873.x.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Leung, D.Y., R.L. Hirsch, L. Schneider, C. Moody, R. Takaoka, S.H. Li, L.A. Meyerson, S.G. Mariam, G. Goldstein, and J.M. Hanifin. 1990. Thymopentin therapy reduces the clinical severity of atopic dermatitis. The Journal of Allergy and Clinical Immunology 85 (5): 927–933.CrossRefPubMedGoogle Scholar
- 25.Jo, S., J. Ryu, H. Kim, M. Kim, M.H. Ryu, H. Kim, and S.I. Cho. 2015. Anti-inflammatory effects of Sanguisorbae Radix on contact dermatitis induced by dinitrofluorobenzene in mice. Chinese Journal of Integrative Medicine. https://doi.org/10.1007/s11655-015-2148-8.
- 26.Lu, Y., J.H. Yang, X. Li, K. Hwangbo, S.L. Hwang, Y. Taketomi, M. Murakami, Y.C. Chang, C.H. Kim, J.K. Son, and H.W. Chang. 2011. Emodin, a naturally occurring anthraquinone derivative, suppresses IgE-mediated anaphylactic reaction and mast cell activation. Biochemical Pharmacology 82 (11): 1700–1708. https://doi.org/10.1016/j.bcp.2011.08.022.CrossRefPubMedGoogle Scholar
- 27.Brandt EB, Sivaprasad U. 2011. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2(3). doi: https://doi.org/10.4172/2155-9899.1000110.
- 28.Lu, Y., Y. Li, M. Jin, J.H. Yang, X. Li, G.H. Chao, H.H. Park, Y.N. Park, J.K. Son, E. Lee, and H.W. Chang. 2012. Inula japonica extract inhibits mast cell-mediated allergic reaction and mast cell activation. Journal of Ethnopharmacology 143 (1): 151–157. https://doi.org/10.1016/j.jep.2012.06.015.CrossRefPubMedGoogle Scholar
- 33.Savinko, T., S. Matikainen, U. Saarialho-Kere, M. Lehto, G. Wang, S. Lehtimäki, P. Karisola, T. Reunala, H. Wolff, A. Lauerma, and H. Alenius. 2012. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. The Journal of Investigative Dermatology 132 (5): 1392–1400. https://doi.org/10.1038/jid.2011.446.CrossRefPubMedGoogle Scholar
- 34.Vocca, L., C. Di Sano, C.G. Uasuf, A. Sala, L. Riccobono, S. Gangemi, G.D. Albano, A. Bonanno, R. Gagliardo, and M. Profita. 2015. IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases. Immunobiology 220 (8): 954–963. https://doi.org/10.1016/j.imbio.2015.02.005.CrossRefPubMedGoogle Scholar
- 36.Nygaard, U., M. Hvid, C. Johansen, M. Buchner, R. Fölster-Holst, M. Deleuran, and C. Vestergaard. 2016. TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis. Journal of the European Academy of Dermatology and Venereology 30 (11): 1930–1938. https://doi.org/10.1111/jdv.13679.PubMedGoogle Scholar